Novanta Inc. (NASDAQ:NOVT – Get Free Report) CFO Robert Buckley sold 1,111 shares of the stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $180.45, for a total transaction of $200,479.95. Following the sale, the chief financial officer now directly owns 120,419 shares in the company, valued at approximately $21,729,608.55. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Robert Buckley also recently made the following trade(s):
- On Tuesday, October 1st, Robert Buckley sold 3,660 shares of Novanta stock. The stock was sold at an average price of $174.01, for a total transaction of $636,876.60.
- On Tuesday, September 3rd, Robert Buckley sold 4,379 shares of Novanta stock. The stock was sold at an average price of $176.20, for a total transaction of $771,579.80.
- On Thursday, August 1st, Robert Buckley sold 4,108 shares of Novanta stock. The shares were sold at an average price of $172.75, for a total value of $709,657.00.
- On Tuesday, July 16th, Robert Buckley sold 1,830 shares of Novanta stock. The stock was sold at an average price of $180.18, for a total value of $329,729.40.
- On Friday, July 12th, Robert Buckley sold 1,830 shares of Novanta stock. The shares were sold at an average price of $170.19, for a total value of $311,447.70.
Novanta Stock Performance
Shares of Novanta stock opened at $171.84 on Friday. The firm has a fifty day moving average of $175.12 and a two-hundred day moving average of $168.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.73 and a current ratio of 2.77. The stock has a market capitalization of $6.17 billion, a price-to-earnings ratio of 89.04 and a beta of 1.29. Novanta Inc. has a 52 week low of $111.20 and a 52 week high of $187.12.
Analysts Set New Price Targets
Separately, Robert W. Baird upped their target price on shares of Novanta from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th.
Read Our Latest Report on NOVT
Institutional Trading of Novanta
Hedge funds have recently modified their holdings of the company. Rise Advisors LLC acquired a new position in Novanta during the first quarter valued at approximately $32,000. Headlands Technologies LLC acquired a new position in shares of Novanta in the 1st quarter valued at $52,000. Signaturefd LLC grew its holdings in shares of Novanta by 38.3% in the 2nd quarter. Signaturefd LLC now owns 361 shares of the technology company’s stock valued at $59,000 after buying an additional 100 shares during the period. YHB Investment Advisors Inc. bought a new stake in shares of Novanta in the 1st quarter valued at $81,000. Finally, Fidelis Capital Partners LLC bought a new position in Novanta during the first quarter worth about $90,000. 98.35% of the stock is currently owned by institutional investors and hedge funds.
Novanta Company Profile
Novanta Inc, together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation.
Read More
- Five stocks we like better than Novanta
- Top Biotech Stocks: Exploring Innovation Opportunities
- When Is the Best Time to Invest in Mutual Funds?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Is NVIDIA Stock in a Correction or Consolidation?
- Where Do I Find 52-Week Highs and Lows?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.